MedTrace Logo

Study of the Efficacy and Safety of IBI319 in Patients With Advanced Malignant Tumors

NCT04708210 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 256

Last updated 2022-10-12

No results posted yet for this study

Summary

An open-label, multicenter, phase Ia/Ib study to evaluate the safety, tolerance and preliminary efficacy of IBI319 in patients with advanced malignant tumors

Conditions

  • Advanced Malignant Tumors

Interventions

DRUG

IBI319

Iv infusion day 1 of every 14 or 21 days in Phase Ia until disease progression or loss of clinical benefit.

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Yilong Wu · Guangdong Provincial People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-28
Primary Completion
2022-12-21
Completion
2023-06-21

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04708210 on ClinicalTrials.gov